Icône BioRender

Autoinjector (Risankizumab)

Autoinjector (Risankizumab) - Editable icon of frontal view of a Risankizumab autoinjector
[{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51522/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51522/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51523/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51523/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51524/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51524/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51525/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51525/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51526/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51526/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51527/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51527/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51528/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51528/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51529/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51529/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152a/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152a/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152b/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152b/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152c/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152c/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152d/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152d/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152e/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152e/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5152f/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5152f/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51530/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51530/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51531/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51531/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51532/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51532/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51533/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51533/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51534/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51534/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51535/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51535/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51536/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51536/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51537/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51537/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51538/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51538/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51539/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51539/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153a/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153a/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153b/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153b/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153c/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153c/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153d/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153d/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153e/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153e/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c5153f/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c5153f/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51540/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51540/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51541/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51541/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51542/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51542/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51543/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51543/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51544/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51544/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51545/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51545/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51546/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51546/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51547/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51547/667b173004e4d095b4c514f1.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/667b177104e4d095b4c51548/667b173004e4d095b4c514f1.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/667b177104e4d095b4c51548/667b173004e4d095b4c514f1.png"}]
Utiliser cette icône – Gratuit
Aucune carte de crédit requise pour l'inscription.

Cette icône est entièrement modifiable dans BioRender

  • Ajoutez du texte, des formes et d'autres icônes
  • Recherchez parmi plus de 50 000 icônes scientifiquement exactes
  • Changez les couleurs et réorganisez chaque icône, ligne et étiquette
  • Exportez ou partagez pour tout type d'utilisation
Scientist Avatars

Rejoignez plus de 4 millions de scientifiques qui créent déjà des figures prêtes à être publiées

Passez des icônes à la figure terminée – en quelques minutes

  • Rechercher à partir de plus de 50 000 icônes scientifiquement exactes et évaluées par des pairs
  • Personnalisez avec des étiquettes, des formes et des icônes supplémentaires – tout est entièrement modifiable
  • Exporter ou partagez vos figures avec vos collaborateurs
    ‍
page dashboard

Ce n'est pas tout à fait l'icône qu'il vous faut ? Découvrez-en plus.

Recherchez parmi plus de 50 000 icônes dans plus de 30 domaines des sciences de la vie.

search icon
arrow-right
Skyrizi,Plaque psoriasis,psoriatic arthritis,Crohn's disease,interleukin 23A,IL-23A,IL-23,cho cell,mutation,mutant,mutated,Leu234Ala,Leu235Ala,lala mutation,double mutation,subcutaneous injection,injection,autoinjection,monoclonal antibody,antibody,antibody drug,antibody drug,drug,antigen,competitor,immunologlobulin,binding agent,monoclonal,immune,immunoglobin,immunological,antigen-binding,nanobody,fabs,neutralizing,polyclonal,therapeutic,immunology,oncology,biochemistry,molecular biology,pharmacology,biotechnology,injector,auto injector,auto-injector,autoinjector,injector device,injector pen,inject,auto syringe,self-injectable,injectable,medication pen,medication,pen,uncapped,needle,metabolic,syndrome,treatment,treat,therapy,tip,medicine,plunger,dose window,selection,dial,dose,disposable,button,chemotherapy,chemo,cancer,at-home,one-use,spring-loaded syringes,syringe,actuator,self-administration,drug delivery,prefilled syringe,intramuscular,subcutaneous,single use,epinephrine,insulin pen,portable injector,Humira,rheumatoid arthritis,psoriasis,Crohn's disease,epipen,medical device,medical equipment,medical instrument,medical apparatus,medical tool,medical appliance,proj-creative-abx-24q2,proj-creative-abx-24q2-AbbVie,Skyrizi,risankizumab,injector pen
Voir plus

Essayez un synonyme, ou inscrivez-vous pour demander une icône depuis l'application.

Types d'images

Autoinjector (Risankizumab) icon JPEG

Autoinjector (Risankizumab) icon PNG

Autoinjector (Risankizumab) icon SVG

Autoinjector (Risankizumab) icon GIF

FAQ sur les icônes BioRender

How are scientists using the Autoinjector (Risankizumab) icon in their work?

BioRender users often use the Autoinjector (Risankizumab) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Lab and Objects.

Puis-je utiliser cette icône dans une figure ou une illustration scientifique BioRender ?

Yes, the Autoinjector (Risankizumab) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Autoinjector (Risankizumab) icon customizable in BioRender?

Most icons in BioRender, including the Autoinjector (Risankizumab) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Autoinjector (Risankizumab) icon for publication or presentations?

Yes, figures containing the Autoinjector (Risankizumab) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Autoinjector (Risankizumab) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Autoinjector (Risankizumab) icon — especially those focused on Lab and Objects. You can search BioRender’s template library or add this icon manually to any canvas.

Qu'est-ce que BioRender ?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Autoinjector (Risankizumab) icon along with our library of more than 30,000 life science icons.

Utiliser cette icône dans BioRender

Créez dès aujourd'hui des illustrations scientifiques professionnelles
antibody elements3D Phospholipid illustration

Vous recherchez du contenu scientifique ?

Parcourez plus de 50 000 icônes et modèles validés par des pairs, faciles à utiliser et gratuits.

Trouvez le vôtre dès maintenant
x icon